tisagenlecleucel

Leah SherwoodTransplantation & Cellular Therapy | November 22, 2022
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Leah SherwoodTransplantation & Cellular Therapy | November 22, 2022
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Advertisement
Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
Kerri FitzgeraldAggressive B-Cell Lymphoma | November 14, 2022
The European Commission has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of ...
Leah LawrenceIndolent B-Cell Lymphoma | November 22, 2022
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
Advertisement
Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022
The CAR T-cell therapy was approved for adult follicular lymphoma patients who have received two or more lines of systemic ...
Ariel DeMaioChronic Lymphocytic Leukemia | February 1, 2023
Two adults who received infusions of anti-CD19 CAR T-cell therapy tisagenlecleucel were in remission at nine and ten years.
Ariel DeMaioPrint | November 29, 2022
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
Advertisement
Advertisement